



Curriculum Vitae

Eric Guglielmo, M.D.
2329 Medico Ln, Suite 103
Melbourne, FL 32940
eric.guglielmo@gmail.com 321-735-8800

Education:

- **Medical Degree**

University of Nevada School of Medicine Reno, NV M.D. May 2005

University of Alaska, Fairbanks, AK Post-baccalaureate Pre-Med 1999-2001

University of Georgia, Athens, GA M.Ed., English Education June 1995

University of Georgia, Athens, GA B.A., English, June 1993

- **Fellowship** (Surgical Retina) West Virginia Eye Institute
West Virginia University, Morgantown, WV
July 2009-June 2010
- **Residency** Dean McGee Eye Institute, University of Oklahoma
Department of Ophthalmology, Oklahoma City, OK
July 2006-June 2009
- **Transitional Internship** Sacred Heart Medical Center
Spokane, WA
July 2005-June 2006
- **Certifications** Board Certified: American Board of Ophthalmology
Initial certification 2012, 10 year recertification completed 2022
- **Licensure State of Florida:** Feb. 01, 2024 exp Jan. 31, 2026 #ME166547



Professional Experience

- **Florida Retina Specialists**
Board Certified Ophthalmologist, Vitreoretinal Surgeon
2329 Medico Ln, Suite 103, Melbourne, FL 32940
280 N. Sykes Creek Pkwy., Suite B, Merritt Island, FL 32953
- **Spokane Eye Clinic**
Board Certified Ophthalmologist, Vitreoretinal Surgeon
Spokane, WA

Research Experience

- **Principal Investigator:** "A Phase 3a Multicenter, Randomized, Double-masked study to assess safety and efficacy of brolocizumab 6 mg q4 weeks compared to aflibercept 2 mg q4 weeks in patients with neovascular age-related macular degeneration (nAMD) with persistent retinal fluid (**MERLIN Trial**)" ClinicalTrials.gov Identifier: NCT03710564.
- **Principal Investigator:** "A Phase 3 Multicenter Randomized, Double-Masked Trial of RTH258 (Brolocizumab) Versus Aflibercept for Neovascular AMD: Efficacy and Safety. (**HAWK Trial**)" NCT02307682.
- **Principal Investigator:** "Phase 3 Study of Safety and Efficacy of Brolocizumab 6 mg Drug Product Intended for Commercialization in Patients With nAMD (**HAWK Extension study**)". NCT03386474.
- **Principal Investigator:** Phase 3 Treatment for CI-DME in Eyes With Very Good VA Study (**DRCR Protocol V**) NCT01909791.
- **Principal Investigator:** Phase 3 Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab, and Ranibizumab for DME (**DRCR Protocol T**) NCT01627249
- **Principal Investigator:** Phase 3 Safety and Efficacy Study of Iontophoretic Dexamethasone Phosphate Ophthalmic Solution to Treat Non-Infectious Anterior Segment Uveitis EyeGate NCT01505088
- **Sub Investigator:** VGFTe(HD)-AMD-1905. A Randomized, Single-Masked, Active-Controlled Phase 2 Study of the Safety, Tolerability, and Efficacy of Repeated Doses of High-Dose Aflibercept in Patients with Neovascular Age-Related Macular Degeneration (CANDELA) NCT04126317



- **Sub-Investigator:** GR 40550 A Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of the Port Delivery System With Ranibizumab (PDS) in Participants With Diabetic Macular Edema (DME) Compared With Intravitreal Ranibizumab (PAGODA) NCT04108156
- **Sub-Investigator:** GR40973 A Phase II, Multicenter, Randomized, Single-Masked, Sham–Controlled Study To Assess Safety, Tolerability, And Efficacy Of Intravitreal Injections Of FHTR2163 In Patients With Geographic Atrophy Secondary To Age-Related Macular Degeneration (Gallego) NCT03972709
- **Sub-Investigator:** GTScope: A Study Of Disease Progression In Genetically Defined Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration NCT03894020
- **Sub-Investigator:** GTScope: A Study Of Disease Progression In Genetically Defined Subjects With Geographic Atrophy Secondary To Age-Related Macular Degeneration NCT03894020
- **Sub-Investigator:** GR40306 (Tenaya): "A Phase III, Multicenter, Randomized, Double-Masked, Active Comparator-Controlled Study to Evaluate the Efficacy and Safety of Faricimab in Patients with Neovascular Age-Related Macular Degeneration (nAMD)" NCT03823287
- **Sub-Investigator:** A Phase III, Randomized, Visual Assessor-Masked, Active-Comparator, Multicenter Evaluation Of The Efficacy, Safety, And Pharmacokinetics Of The Port Delivery System For Continuous Delivery Of Ranibizumab In Patients With Neovascular Age-Related Macular Degeneration (ARCHWAY) NCT03677934
- **Sub-Investigator:** APL2-303: A Phase III, Multi-Center, Randomized, Double-Masked, Sham-Controlled Study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy with Sham Injections in Patients with Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (AMD)(DERBY) NCT03525600
- **Sub-Investigator:** CRTH258B2301: A Two-Year, Three-arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolocizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema. (Kestrel) NCT03481634
- **Sub-Investigator:** CRTH258B2301: A Two-Year, Three-arm, Randomized, Double-Masked, Multicenter, Phase III Study Assessing the Efficacy and Safety of Brolocizumab versus Aflibercept in Adult Patients with Visual Impairment due to Diabetic Macular Edema. (Kestrel) NCT03481634
- **Sub-Investigator:** KHB-1801 - A Multicenter, Double-Masked, Randomized, Dose-Ranging Trial to Evaluate the Efficacy and Safety of Conbercept Intravitreal Injection in Subjects With Neovascular Age-related Macular Degeneration (PANDA) NCT03577899
- **Sub-Investigator:** Phase 3 Aflibercept vs. Bevacizumab + Deferred Aflibercept for the Treatment of CI-DME (DRCR AC) ClinicalTrials.gov Identifier: NCT03321513
- **Sub-Investigator:** Phase 3 Study of the Efficacy and Safety of Intravitreal (IVT) Aflibercept for the Improvement of Moderately Severe to Severe Nonproliferative Diabetic Retinopathy (NPDR) (PANORAMA) NCT02718326



- **Sub-Investigator:** Open Label Long-Term Safety of Lampalizumab Intravitreal (ITV) Injections in Participants With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration (OMASPECT) NCT02745119
- **Sub-Investigator:** Phase 2 AVENUE: A Proof-of-Concept Study of RG7716 in Participants With Choroidal Neovascularization (CNV) Secondary to Age-Related Macular Degeneration (AMD) NCT02484690
- **Sub-Investigator:** A Phase 2 Study of RO6867461 in Participants With Center-Involving Diabetic Macular Edema (CI-DME) (BOULEVARD) NCT02699450
- **Sub-Investigator:** Phase 2 A Clinical Trial Designed to Evaluate the Safety and Efficacy Study of Luminate® in Inducing PVD (Posterior Vitreous Detachment) in Non-Proliferative Diabetic Retinopathy NCT02435862
- **Sub-Investigator:** Phase 3 A Study Investigating the Efficacy and Safety of Lampalizumab Intravitreal Injections in Patients With Geographic Atrophy Secondary to Age-Related Macular Degeneration (CHROMA) NCT02247479
- **Sub-Investigator:** A Phase 2 Randomized, Controlled, Double-Masked, Multicenter Clinical Trial Designed to Evaluate the Safety and Exploratory Efficacy of Luminate® (ALG-1001) as Compared to Avastin® and Focal Laser Photocoagulation in the Treatment of Diabetic Macular Edema NCT02348918
- **Sub-Investigator:** Phase 3 Safety and Efficacy of Abicipar Pegol in Patients With Neovascular Age-related Macular Degeneration (SEQUOIA) NCT02462486
- **Sub-Investigator:** Phase 2 Efficacy and Safety Study of iSONEP With & Without Lucentis/Avastin/Eylea to Treat Wet AMD (Nexus) NCT01414153
- **Sub-Investigator:** Phase 2 A Randomized, Multi-center, Phase II Study of the Safety, Tolerability and Bioactivity of Repeated Intravitreal Injections of iCo-007 as Monotherapy or in Combination With Ranibizumab or Laser Photocoagulation in the Treatment of Diabetic Macular Edema (the iDEAL Study) NCT01565148
- **Sub-Investigator:** Phase 2 Prompt Panretinal Photocoagulation Versus Ranibizumab+Deferred Panretinal Photocoagulation for Proliferative Diabetic Retinopathy (Protocol S) NCT01489189



- **University of Nevada School of Medicine**
Transport of the neurotrophins NGF and BDNF in the visual system of chick embryos.
Preceptor: Christopher Von Bartheld, MD. May-August, 2002
Description: Investigated the transport kinetics of BDNF and NGF in the developing visual system of chick embryos through the use of radioactive iodination. Iodinated neurotrophic factor was injected into the vitreous of the eye and the time delay of peak arrival in the brain was measured by recording radioactivity levels.
- **University of Alaska, Fairbanks**
Comparison of calculated and actual measurements of electrochemical bonds using various computational chemistry methods on the Cray J-90 supercomputer.
Preceptor: John Keller, Ph.D.
Description: Performed molecular modeling of various compounds on the Cray J-90 supercomputer using the Gaussian program. Results of the predicted electrochemical bond lengths and angles were then compared to actual results obtained from x-ray crystallography.
- **Dean McGee Eye Institute** Primary vitrectomy vs. scleral buckle. A comparison of outcomes.
Preceptor: Robert Leonard, MD.
Retrospective chart review comparing the outcomes of retinal detachments repaired by primary vitrectomy with retinopexy vs. those that also received a scleral buckle.

Abstracts

- C.S. von Bartheld, H.B. Rind, E.S. Guglielmo, R. Butowt. Fates of retrogradely transported proteins: degradation or recycling? International Journal of Developmental Neuroscience [Int. J. Dev. Neurosci.]. Symposium abstract. (2004).

Presentations

- Guglielmo E, Leonard, R. Primary small-gauge vitrectomy vs. traditional scleral buckling techniques, a comparison of outcomes. Dean McGee Eye Institute Resident Alumni
- Butowt, R, Guglielmo E, C.S von Bartheld. Fates of retrogradely transported neurotrophins: Receptor binding, ultrastructural localization and degradation in visual pathways. Sixth IBRO World Congress of Neuroscience. Prague, CZ.
- Guglielmo E, von Bartheld C. Accumulation kinetics of axonally transported neurotrophins in the visual system of chick embryos. George Bierkamper Student Research Convocation



Professional Organizations

- American Academy of Ophthalmology
- American Society of Retinal Specialists
- Christian Ophthalmology Society
- Alpha Omega Alpha Medical Honor Society

Honors and Awards

- **Top Doctor, 2021. Spokane Coeur D'Alene Magazine**
Awarded to select physicians of the Inland Northwest, as voted on by their peers
- **Dean McGee Eye Institute**
Resident Teaching Award, 2009
- **University of Nevada School of Medicine**
Alpha Omega Alpha Honor Society, elected as a junior, April 2004
Outstanding Medical Student in Biochemistry, 2002
Outstanding Medical Student in Psychiatry and Behavioral Sciences, 2005
Outstanding Medical Student in Neurosciences, 2005
McGraw-Hill Appleton Lange Book Award, 2002
Awarded to 2 top freshman medical students as chosen by faculty
Barbara H. O'Rourke Memorial Award, 2005
\$5,000 award given to an outstanding graduating student
- **University of Alaska, Fairbanks**
President's List, Summer and Fall 1999, Spring 2000
Awarded to full-time students with a 4.0 GPA.
- **University of Georgia**
Kappa Delta Phi Educational Honor Society
Kappa Delta Epsilon Educational Honor Society